Phaseline

Companies › Biofrontera

Biofrontera: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Oncology; next expected readout Feb 2029.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
BF-200 ALA (Ameluz®)
5-aminolevulinic acid (ALA) prodrug; converted to protoporphyrin IX (PPIX) for photodynami
PPIXPhase 3Superficial Basal Cell Carcinoma; Locally Advanced Colorectal CarcinomaFeb 2029

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03573401BF-200 ALA (Ameluz®)Phase 3Superficial Basal Cell CarcinomaOncologyFeb 2029
NCT06307548BF-200 ALA (Ameluz®)Phase 1Locally Advanced Colorectal CarcinomaOncologyJun 2029

From the company's SEC filings

Cash of $5m on 2026-06-30; operating cash outflow about $4m a year; runway about 16 months at that burn, to Oct 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Regulatory dates the company has stated

Private offerings reported to the SEC (Form D)

Agreements filed with the SEC (item 1.01), last two years

Targets

PPIX (1)

Companies with the same targets

–

Companies built like this

Lakefront Biotherapeutics GT Medical Technologies Suzhou Immunofoco Biotechnology CG Oncology GeoVax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.